Orchestra BioMed Holdings (OBIO) EBITDA Margin (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly EBITDA Margin came in at 20069.09% in Q1 2026, down 1788925.0% year-on-year from N/an in Q1 2025, and down 91967.94% on a QoQ basis from 21.85% in Q4 2025.
Orchestra BioMed Holdings (OBIO) EBITDA Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of EBITDA Margin data on file, last reported at 20069.09% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 1788925.0% year-over-year to 20069.09% in Q1 2026; TTM through Mar 2026 was 167.96%, a 221593.0% increase from a year earlier, with the FY2025 full-year figure at 154.73%, up 228276.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 20069.09%, down from 21.85% in the prior quarter.
- Over the last five years, EBITDA Margin for OBIO reached as high as 21.85% in Q4 2025 and fell as low as 20069.09% in Q1 2026.
- Historically, EBITDA Margin has averaged 3207.6% across 5 years, with a median of 2166.97% in 2024.
- Across the five-year window, EBITDA Margin surged 661355 bps in 2025 and plunged 1788925 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 891.02% in 2022, then plunged by 435 bps to 4763.74% in 2023, then tumbled by 38 bps to 6591.7% in 2024, then jumped by 100 bps to 21.85% in 2025, then plunged by 91968 bps to 20069.09% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 20069.09% in Q1 2026, 21.85% in Q4 2025, and 2359.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | -20,069.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,069.09% |
| Dec 31, 2025 | 21.85% |
| Sep 30, 2025 | -2,359.23% |
| Jun 30, 2025 | -2,311.84% |
| Mar 31, 2025 | -2,179.84% |
| Dec 31, 2024 | -6,591.70% |
| Sep 30, 2024 | -1,655.72% |
| Jun 30, 2024 | -2,166.97% |
| Mar 31, 2024 | -2,326.29% |
| Dec 31, 2023 | -4,763.74% |
| Sep 30, 2023 | -3,466.35% |
| Jun 30, 2023 | -1,415.96% |
| Mar 31, 2023 | -991.84% |
| Dec 31, 2022 | -891.02% |
| Sep 30, 2022 | -865.61% |
| Jun 30, 2022 | -1,903.74% |
| Mar 31, 2022 | -592.15% |